WO2000007038A3 - Protein fragment complementation assays - Google Patents

Protein fragment complementation assays Download PDF

Info

Publication number
WO2000007038A3
WO2000007038A3 PCT/CA1999/000702 CA9900702W WO0007038A3 WO 2000007038 A3 WO2000007038 A3 WO 2000007038A3 CA 9900702 W CA9900702 W CA 9900702W WO 0007038 A3 WO0007038 A3 WO 0007038A3
Authority
WO
WIPO (PCT)
Prior art keywords
dhfr
murine
assay
zipper
leucine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA1999/000702
Other languages
French (fr)
Other versions
WO2000007038A9 (en
WO2000007038A2 (en
Inventor
Stephen William Watso Michnick
Joelle Nina Pelletier
Ingrid Remy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Montreal
Original Assignee
Universite de Montreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA002244349A external-priority patent/CA2244349A1/en
Priority claimed from US09/124,850 external-priority patent/US6294330B1/en
Priority to DK99936199.1T priority Critical patent/DK1027608T3/en
Application filed by Universite de Montreal filed Critical Universite de Montreal
Priority to AU51430/99A priority patent/AU5143099A/en
Priority to AT99936199T priority patent/ATE456054T1/en
Priority to EP99936199A priority patent/EP1027608B1/en
Priority to DE69941946T priority patent/DE69941946D1/en
Publication of WO2000007038A2 publication Critical patent/WO2000007038A2/en
Publication of WO2000007038A3 publication Critical patent/WO2000007038A3/en
Publication of WO2000007038A9 publication Critical patent/WO2000007038A9/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

A Protein Complementation Assay/Universal Reporter System (PCA/URS) for detecting and screening for agonists and antagonists of a cellular receptor is described. The invention is illustrated by the example of murine dihydrofolate reductase (DHFR). Fusion peptides consisting of N- and C terminal fragments of murine DHFR fused to GCN4 leucine zipper sequences were coexpressed in Escherichia coli grown in minimal medium, where the endogenous DHFR activity was inhibited with trimethoprim. Coexpression of the complementary fusion products restored colony formation. Survival only occured when both DHFR fragments were present and contained leucine-zipper forming sequences, demonstrating that reconstitution of enzyme activity requires assistance of leucine zipper formation. This assay could be used to study equilibrium and kinetic aspects of various molectlar interactions.
PCT/CA1999/000702 1998-07-30 1999-07-30 Protein fragment complementation assays Ceased WO2000007038A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
DE69941946T DE69941946D1 (en) 1998-07-30 1999-07-30 EIWEISBRUCHSTÜCKERGÄNZUNGSTESTS
EP99936199A EP1027608B1 (en) 1998-07-30 1999-07-30 Protein fragment complementation assays
DK99936199.1T DK1027608T3 (en) 1998-07-30 1999-07-30 Protein fragment complementation assays
AU51430/99A AU5143099A (en) 1998-07-30 1999-07-30 Protein fragment complementation assays for the detection of biological or drug interactions
AT99936199T ATE456054T1 (en) 1998-07-30 1999-07-30 PROTEIN FRUITS SUPPLEMENTATION TESTS

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CA002244349A CA2244349A1 (en) 1998-07-30 1998-07-30 Protein fragment complementation assays for the detection of biological or drug interactions
CA2,244,349 1998-07-30
US09/124,850 1998-07-30
US09/124,850 US6294330B1 (en) 1997-01-31 1998-07-30 Protein fragment complementation assays for the detection of biological or drug interactions

Publications (3)

Publication Number Publication Date
WO2000007038A2 WO2000007038A2 (en) 2000-02-10
WO2000007038A3 true WO2000007038A3 (en) 2000-05-04
WO2000007038A9 WO2000007038A9 (en) 2000-07-27

Family

ID=25680408

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1999/000702 Ceased WO2000007038A2 (en) 1998-07-30 1999-07-30 Protein fragment complementation assays

Country Status (3)

Country Link
EP (1) EP1027608B1 (en)
AU (1) AU5143099A (en)
WO (1) WO2000007038A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020064769A1 (en) * 2000-10-05 2002-05-30 Watson Michnick Stephen William Dynamic visualization of expressed gene networks in living cells
EP1101112B1 (en) 1998-07-28 2004-10-06 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Leptin-mediated gene-induction
US8148110B2 (en) 1999-03-15 2012-04-03 The Board Of Trustees Of The Leland Stanford Junior University Detection of molecular interactions by β-lactamase reporter fragment complementation
AU6045900A (en) * 1999-05-25 2000-12-12 Panorama Research, Inc. Interaction-activated proteins
WO2001001137A1 (en) 1999-06-30 2001-01-04 Children's Medical Center Corporation Fusion protein and uses thereof
CA2397162A1 (en) 2000-01-13 2001-07-19 Kalobios, Inc. Circularly permutated, interaction-activated proteins
WO2001088168A2 (en) * 2000-05-12 2001-11-22 Odyssey Pharmaceuticals, Inc. Mapping molecular interactions in plants with protein fragments complementation assays
EP1283878B1 (en) 2000-05-22 2005-07-27 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Receptor-based interaction trap
ES2605445T3 (en) 2001-11-26 2017-03-14 Hivih Protein-protein interactions in the human immunodeficiency virus
BR0317538A (en) 2002-12-20 2005-11-29 Amgen Inc Binding agent, polynucleotide sequence, expression vector, host cell, pharmaceutical composition, and methods of inhibiting myostatin activity, increasing lean muscle mass and lean to fat ratio, treating muscle wasting disease is a myostatin-related metabolic disorder in an individual, detecting and measuring myostatin in a sample, and diagnosing a myostatin-related disorder in an individual
EP1812038A1 (en) 2004-11-18 2007-08-01 VIB vzw Fibronectin iii domain as leptin receptor antagonists
EP2215227A2 (en) * 2007-11-05 2010-08-11 Promega Corporation Hybrid fusion reporter and uses thereof
WO2016160791A1 (en) * 2015-03-30 2016-10-06 Intrexon Corporation Ligand inducible polypeptide coupler system
CN114136944B (en) * 2021-12-10 2023-10-24 山东理工大学 Preparation method of fluorescent aptamer sensor for detecting kanamycin residues in milk
CN115851982B (en) * 2022-11-23 2024-07-19 安徽农业大学 Long-distance molecular genetic marker for chickens and application thereof
KR20240125853A (en) * 2023-02-10 2024-08-20 서울대학교산학협력단 Protein engineering strategies for medical tyrosinase and applications thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998034120A1 (en) * 1997-01-31 1998-08-06 Universite De Montreal Protein fragment complementation assays to detect biomolecular interactions
WO1998044350A1 (en) * 1997-04-02 1998-10-08 The Board Of Trustees Of The Leland Stanford Junior University Detection of molecular interactions by reporter subunit complementation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998034120A1 (en) * 1997-01-31 1998-08-06 Universite De Montreal Protein fragment complementation assays to detect biomolecular interactions
WO1998044350A1 (en) * 1997-04-02 1998-10-08 The Board Of Trustees Of The Leland Stanford Junior University Detection of molecular interactions by reporter subunit complementation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PELLETIER J N ET AL: "A PROTEIN COMPLEMENTATION ASSAY FOR DETECTION OF PROTEIN-PROTEIN INTERACTIONS IN VIVO", PROTEIN ENGINEERING,GB,OXFORD UNIVERSITY PRESS, SURREY, vol. 10, no. SUPPL. 01, - 1 October 1997 (1997-10-01), pages 89, XP002064563, ISSN: 0269-2139 *
ROSSI F ET AL: "MONITORING PROTEIN-PROTEIN INTERACTIONS IN INTACT EUKARYOTIC CELLS BY BETA-GALACTOSIDASE COMPLEMENTATION", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,US,NATIONAL ACADEMY OF SCIENCE. WASHINGTON, vol. 94, - August 1997 (1997-08-01), pages 8405-8410, XP002064565, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
EP1027608A2 (en) 2000-08-16
EP1027608B1 (en) 2010-01-20
AU5143099A (en) 2000-02-21
WO2000007038A9 (en) 2000-07-27
WO2000007038A2 (en) 2000-02-10

Similar Documents

Publication Publication Date Title
WO2000007038A3 (en) Protein fragment complementation assays
EP1605042A3 (en) Compositions for protein fragment complementation assays to detect biomolecular interactions
Lavdovskaia et al. Dual function of GTPBP6 in biogenesis and recycling of human mitochondrial ribosomes
Miller et al. Kinetochore-associated Stu2 promotes chromosome biorientation in vivo
EP1229047A3 (en) IL-1 Receptor fusion proteins used as antagonists and methods of making and using
Huse et al. Semisynthesis of hyperphosphorylated type I TGFβ receptor: addressing the mechanism of kinase activation
US20030165825A1 (en) Interaction-activated, circularly permutated proteins
Goeden-Wood et al. Improved assembly of multimeric genes for the biosynthetic production of protein polymers
NZ508863A (en) Generation of multiple gene products from chimeric fusion proteins by cleavage with ubiquitous endoproteases
US6479289B2 (en) Mammalian two-hybrid system
Tan et al. Preparation and purification of mono-ubiquitinated proteins using Avi-tagged ubiquitin
CA2427747A1 (en) Affinity maturation by competitive selection
US8048986B2 (en) Reversed mammalian protein-protein interaction trap
Preugschat et al. Kinetic analysis of the effects of mutagenesis of W501 and V432 of the hepatitis C virus NS3 helicase domain on ATPase and strand-separating activity
US20060281133A1 (en) Targeted fusion proteins and methods for the characterization of cellular membrane domains
CN104169418A (en) Peptides having affinity for silicon nitride (SI3N4) and uses thereof
US20050130262A1 (en) Mutated photoproteins and their uses
ROJO-NIERSBACH et al. A new method for the selection of protein interactions in mammalian cells
Bruckner et al. Coupled kinetics of ATP and peptide hydrolysis by Escherichia coli FtsH protease
Groll et al. Towards multiplexed protein–protein interaction analysis using protein tag-specific nanobodies
DE69941946D1 (en) EIWEISBRUCHSTÜCKERGÄNZUNGSTESTS
Nam et al. Expression of cloned cDNA for the human mitochondrial RNA polymerase in Escherichia coli and purification
Moser et al. Cell-free protein production of a gamma secretase homolog
WO1999052941A3 (en) Polypeptide domains capable of binding rho protein and their use in assays
WO2003058197A3 (en) Detection of molecular interactions by beta-lactamase reporter fragment complementation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1999936199

Country of ref document: EP

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1-79, DESCRIPTION, REPLACED BY NEW PAGES 1-75; PAGES 80-90, CLAIMS, REPLACED BY NEW PAGES 76-86; PAGES 1/12-12/12, DRAWINGS, REPLACED BY NEW PAGES 1/12-12/12; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWP Wipo information: published in national office

Ref document number: 1999936199

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA